Search Elevated Serum Alkaline Phosphatase as a Marker of Prenatal Intervillositis Chronic Histiocytic

Search Elevated Serum Alkaline Phosphatase as a Marker of Prenatal Intervillositis Chronic Histiocytic (IHC)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02668120

Acronym

IHC

Enrollment

Registered

2016-01-29

Start date

2016-04-16

Completion date

2017-04-11

Last updated

2018-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Histiocytosis

Keywords

chronic histiocytic intervillositis, serum alkaline phosphatase, placenta, case-control study

Brief summary

Background : Chronic histiocytic intervillositis is a rare placental disease linked with poor perinatal outcome. In a recent study, a major antenatal increased alkaline phosphatase was suspected in patients affected by chronic histiocytic intervillositis. This increase may correspond to the release of alkaline phosphatase by the syncytiotrophoblaste prejudiced in this pathology. Aim : To confirm the association between high levels of alkaline phosphatase and the occurrence of chronic histiocytic intervillositis.

Detailed description

Single-center study of case-control comparing three groups of patients matched for gestational age at the time of sampling. The case group will be composed of patients who experienced chronic histiocytic intervillositis which an alkaline phosphatase assay is available during pregnancy (retrospective recruitment). Two control groups will be prospectively: The first will include patients whose pregnancy is low risk. The second will consist of pathological pregnancies (IUGR, Preeclampsia and Death In Utero). All patients will have a blood sample with determination of serum alkaline phosphatase activity and examination of the placenta at delivery.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patient aged 18 years or more * Having signed a free and informed consent * Enjoying a social security scheme Inclusion criteria for cases: * Patient who gave birth at the Lille University Hospital between 2000 and 2009. * Lesion of intervillositis chronic histiocytic (IHC) diagnosed during histological examination of the placenta. * An alkaline phosphatase assay during pregnancy is available and has been achieved at University Hospital of Lille. * Prior information and not opposition of the patient to the secondary use of data collected in medical file. Inclusion criteria for low-risk pregnancy : * No pathological obstetric history, no current pregnancy complications * Followed antenatal clinics at the Lille University Hospital * A gestational age corresponding to one of the cases (pairing ± 1 week) * No chronic intervillositis after pathological examination of the placenta Inclusion criteria for high-risk pregnancy: * Patient hospitalized in the maternal-fetal pathology of the Lille University Hospital Service * Presence of IUGR, Death in Utero or severe preeclampsia with fetal repercussion * A gestational age corresponding to one of the cases (pairing ± 1 week) * No chronic intervillositis after pathological examination of the placenta

Exclusion criteria

* Twin pregnancy * Liver disease in the interrogation * Lack of consent of the patient * Patient not covered by a social security scheme * Patient minor * Patient under guardianship

Design outcomes

Primary

Measure	Time frame
Number of subjects with alkaline phosphatase levels greater than or equal to 5 times the normal	At the time of inclusion

Countries

France

Outcome results